Literature DB >> 30573850

ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion.

Kenneth Tou En Chang1,2, Amos Zhi En Tay3, Chik Hong Kuick3, Huiyi Chen3, Elizabeth Algar4,5, Nadine Taubenheim4, Janine Campbell6, Francoise Mechinaud7, Martin Campbell7, Leanne Super7, Chavit Chantranuwat8, S T Yuen9, John K C Chan10, Chung W Chow11,12.   

Abstract

In 2008, we presented three cases of ALK-positive histiocytosis as a novel systemic histiocytic proliferation of early infancy with hepatosplenomegaly and dramatic hematological disturbances. This series of 10 cases (including the original three cases) describes an expanded clinicopathological spectrum and the molecular findings of this histiocytic proliferation. Six patients had disseminated disease: five presented in early infancy with eventual disease resolution, and the sixth presented at 2 years of age and died of intestinal, bone marrow, and brain involvement. The other four patients had localized disease involving nasal skin, foot, breast, and intracranial cavernous sinus - the first three had no recurrence after surgical resection, while the cavernous sinus lesion showed complete resolution with crizotinib therapy. The lesional histiocytes were very large, with irregularly folded nuclei, fine chromatin, and abundant eosinophilic cytoplasm, sometimes with emperipolesis. There could be an increase in foamy histiocytes and Touton giant cells with time, resembling juvenile xanthogranuloma. Immunostaining showed that the histiocytes were positive for ALK, histiocytic markers (CD68, CD163) and variably S100, while being negative for CD1a, CD207, and BRAF-V600E. Next-generation sequencing-based anchored multiplex PCR (Archer® FusionPlex®) performed in six cases identified KIF5B-ALK gene fusion in five and COL1A2-ALK fusion in one. There was no correlation of gene fusion type with disease localization or dissemination. The clinicopathological spectrum of ALK-positive histiocytosis is broader than originally described, and this entity is characterized by frequent presence of KIF5B-ALK gene fusion. We recommend that every unusual histiocytic proliferative disorder, especially disseminated lesions, be tested for ALK expression because of the potential efficacy of ALK inhibitor therapy in unresectable or disseminated disease.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30573850     DOI: 10.1038/s41379-018-0168-6

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  18 in total

1.  ALK-positive histiocytosis with KIF5B-ALK fusion in an adult female.

Authors:  Gaurav K Gupta; Liqiang Xi; Svetlana D Pack; Jennifer B Jones; Stefania Pittaluga; Mark Raffeld; Elaine S Jaffe
Journal:  Haematologica       Date:  2019-08-01       Impact factor: 9.941

2.  ALK-positive histiocytosis with KIF5B-ALK fusion in the central nervous system.

Authors:  Calixto-Hope G Lucas; Ahmed Gilani; David A Solomon; Xiayuan Liang; Ossama M Maher; Gabriel Chamyan; Bette K Kleinschmidt-Demasters; Arie Perry
Journal:  Acta Neuropathol       Date:  2019-05-22       Impact factor: 17.088

3.  Histiocytoses converge through common pathways.

Authors:  Elaine S Jaffe; John K C Chan
Journal:  Blood       Date:  2022-01-13       Impact factor: 22.113

Review 4.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Authors:  Joseph D Khoury; Eric Solary; Oussama Abla; Yassmine Akkari; Rita Alaggio; Jane F Apperley; Rafael Bejar; Emilio Berti; Lambert Busque; John K C Chan; Weina Chen; Xueyan Chen; Wee-Joo Chng; John K Choi; Isabel Colmenero; Sarah E Coupland; Nicholas C P Cross; Daphne De Jong; M Tarek Elghetany; Emiko Takahashi; Jean-Francois Emile; Judith Ferry; Linda Fogelstrand; Michaela Fontenay; Ulrich Germing; Sumeet Gujral; Torsten Haferlach; Claire Harrison; Jennelle C Hodge; Shimin Hu; Joop H Jansen; Rashmi Kanagal-Shamanna; Hagop M Kantarjian; Christian P Kratz; Xiao-Qiu Li; Megan S Lim; Keith Loeb; Sanam Loghavi; Andrea Marcogliese; Soheil Meshinchi; Phillip Michaels; Kikkeri N Naresh; Yasodha Natkunam; Reza Nejati; German Ott; Eric Padron; Keyur P Patel; Nikhil Patkar; Jennifer Picarsic; Uwe Platzbecker; Irene Roberts; Anna Schuh; William Sewell; Reiner Siebert; Prashant Tembhare; Jeffrey Tyner; Srdan Verstovsek; Wei Wang; Brent Wood; Wenbin Xiao; Cecilia Yeung; Andreas Hochhaus
Journal:  Leukemia       Date:  2022-06-22       Impact factor: 12.883

Review 5.  Histiocytic disorders.

Authors:  Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen
Journal:  Nat Rev Dis Primers       Date:  2021-10-07       Impact factor: 65.038

6.  ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib.

Authors:  Charlotte Syrykh; Loïc Ysebaert; Sarah Péricart; Solène M Evrard; Fabienne Meggetto; Salim Kanoun; Pierre Brousset; Camille Laurent
Journal:  Virchows Arch       Date:  2020-10-03       Impact factor: 4.064

Review 7.  MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age.

Authors:  Rikhia Chakraborty; Omar Abdel-Wahab; Benjamin H Durham
Journal:  Cold Spring Harb Perspect Med       Date:  2021-05-03       Impact factor: 6.915

8.  Localized ALK-positive histiocytosis in a Chinese woman: report of a case in the lung with a novel EML4-ALK rearrangement.

Authors:  Yanhua Bai; Wei Sun; Dongfeng Niu; Xin Yang; Xinting Diao; Yang Yu; Dongmei Lin
Journal:  Virchows Arch       Date:  2021-04-07       Impact factor: 4.064

9.  ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.

Authors:  Paul G Kemps; Jennifer Picarsic; Benjamin H Durham; Zofia Hélias-Rodzewicz; Laura Hiemcke-Jiwa; Cor van den Bos; Marianne D van de Wetering; Carel J M van Noesel; Jan A M van Laar; Robert M Verdijk; Uta E Flucke; Pancras C W Hogendoorn; F J Sherida H Woei-A-Jin; Raf Sciot; Andreas Beilken; Friedrich Feuerhake; Martin Ebinger; Robert Möhle; Falko Fend; Antje Bornemann; Verena Wiegering; Karen Ernestus; Tina Méry; Olga Gryniewicz-Kwiatkowska; Bozenna Dembowska-Baginska; Dmitry A Evseev; Vsevolod Potapenko; Vadim V Baykov; Stefania Gaspari; Sabrina Rossi; Marco Gessi; Gianpiero Tamburrini; Sébastien Héritier; Jean Donadieu; Jacinthe Bonneau-Lagacherie; Claire Lamaison; Laure Farnault; Sylvie Fraitag; Marie-Laure Jullié; Julien Haroche; Matthew Collin; Jackie Allotey; Majid Madni; Kerry Turner; Susan Picton; Pasquale M Barbaro; Alysa Poulin; Ingrid S Tam; Dina El Demellawy; Brianna Empringham; James A Whitlock; Aditya Raghunathan; Amy A Swanson; Mariko Suchi; Jon M Brandt; Nabeel R Yaseen; Joanna L Weinstein; Irem Eldem; Bryan A Sisk; Vaishnavi Sridhar; Mandy Atkinson; Lucas R Massoth; Jason L Hornick; Sanda Alexandrescu; Kee Kiat Yeo; Kseniya Petrova-Drus; Stephen Z Peeke; Laura S Muñoz-Arcos; Daniel G Leino; David D Grier; Robert Lorsbach; Somak Roy; Ashish R Kumar; Shipra Garg; Nishant Tiwari; Kristian T Schafernak; Michael M Henry; Astrid G S van Halteren; Oussama Abla; Eli L Diamond; Jean-François Emile
Journal:  Blood       Date:  2022-01-13       Impact factor: 22.113

Review 10.  Histiocytosis.

Authors:  Jean-François Emile; Fleur Cohen-Aubart; Matthew Collin; Sylvie Fraitag; Ahmed Idbaih; Omar Abdel-Wahab; Barrett J Rollins; Jean Donadieu; Julien Haroche
Journal:  Lancet       Date:  2021-04-23       Impact factor: 202.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.